araag2/HINT huggingface dataset:
Clinical trial NCT00659438 (phase 2, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: zd6474 (vandetanib), bicalutamide, placebo
SMILES: COC1=C(OCC2CCN(C)CC2)C=C2N=CN=C(NC3=C(F)C=C(Br)C=C3)C2=C1, [H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=C(O)C=C1)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males presented with a confirmed histological diagnosis of adenocarcinoma of the
             prostate with evidence of metastases (including bone, lymph nodes, or other site)
             radiologically or histologically documented and despite a serum testosterone ≤1.73
             nmol/L (50 ng/dL) proving castration, evidence of biochemical progression of prostate
             cancer, documented by a rise in PSA .

        Exclusion Criteria:

          -  Radiotherapy or surgery or antiandrogens (except LHRH analogue) or bilateral
             orchiectomy within the 30 days preceding Visit 1. Incompletely healed surgical
             incision.

          -  Concomitant anticancer therapy other than surgical castration or continuous medical
             castration.

          -  Biology restriction.

          -  Clinical significant cardiovascular event or presence of cardiac disease that in the
             opinion of the Investigator increases the risk of ventricular arrhythmia.

          -  History of arrhythmia which is symptomatic or requires treatment (CTCAE grade 3),
             symptomatic despite treatment, or asymptomatic sustained ventricular tachycardia.
             Subjects with atrial fibrillation controlled on medication are permitted.

          -  Hypertension not controlled by medical therapy

          -  ECG /QTc prolongation

          -  Presence of left bundle branch block (LBBB).
Clinical trial NCT00403637 (phase 2/phase 3, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: indacaterol maleate
SMILES: CCC1=C(CC)C=C2CC(CC2=C1)NC[C@H](O)C1=C2C=CC(=O)NC2=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females 12 - 75 years of age with a diagnosis of persistent asthma

          -  Daily treatment with a bronchodilator and daily dose of at least 100 µg beclomethasone
             dipropionate or equivalent

          -  FEV1 at Visit 1 at least 50% of the predicted normal value

          -  FEV1 reversibility at least 15%

        Exclusion Criteria:

          -  Use of tobacco products within 6 months prior to Visit 1 or a smoking history of more
             than 10 pack years

          -  Chronic Obstructive Pulmonary Disease (COPD)

          -  Seasonal allergy where asthma is likely to deteriorate during the period of the study

          -  Emergency room treatment for an acute asthma attack within the previous 6 weeks or
             hospitalized within the previous 6 months

          -  A respiratory tract infection within the previous 6 weeks Other protocol-defined
             exclusion criteria may apply
Clinical trial NCT00554970 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: map0010 low dose, map0010 high dose, budesonide inhalation suspension 0.25mg, budesonide inhalation suspension 0.5mg
SMILES: [H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, [H][C@@]12C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female adult asthmatics with mild to moderate persistent asthma.

          -  18 to 45 (up to the 46th birthday) years of age.

          -  Documented diagnosis of asthma at least 3 months prior to Visit 1, per NIH/NHLBI,
             EPR-3 criteria.

          -  Able to withhold short-acting bronchodilators (e.g., albuterol or ipratropium bromide)
             for at least 4 hours prior to clinic visits.

          -  Baseline FEV1 greater than or equal to 50% of predicted normal.

        Exclusion Criteria:

          -  Any other significant illness/abnormality

          -  A history of upper or lower respiratory tract infection within 2 weeks

          -  A history of acute or severe asthma attack requiring ICU admission or ventilatory
             support.
Clinical trial NCT01466361 (phase 2, status: completed)
Conditions: smoking, smoking cessation
ICD codes: O99.334, O99.335, Y93.G2, O99.330, O99.331, O99.332, O99.333, Y36.881S, Y36.891S, Y36.880S, Y36.881A, Y36.881D, Y36.890S, Y36.891A
Drugs: nicotine lower dose, nicotine higher dose, placebo
SMILES: CC(=O)NC1=CC=C(O)C=C1, CC(=O)NC1=CC=C(O)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Generally healthy smokers who smoke more than 5 cigarettes per day

          -  Body mass index (BMI) within the range 19-35 kilogram (kg)/meter (m)^2

          -  Females of childbearing potential who are, in the opinion of the investigator,
             practicing a reliable method of contraception.

        Exclusion Criteria:

          -  Women who are pregnant or who have a positive urine pregnancy test.

          -  Participants with known or suspected intolerance or hypersensitivity to the study
             materials (or closely related compounds) or any of their stated ingredients.

          -  Clinical Study/Experimental Medication: Participation in another clinical study or
             receipt of an investigational drug within 30 days of the screening visit.

          -  Prior Concomitant Medication: Treatment with enzyme altering agents (e.g.
             carbamazepine, phenytoin, cimetidine, sodium valporate) within 30 days of the craving
             provocation visit; Use of any prescription psychoactive medication (such as but not
             limited to antidepressants, antipsychotics, anxiolytics) within 14 days of the craving
             provocation visit; Participant has used an over-the-counter (OTC) medication such as
             antihistamines, sedating agents, or any compound that would have a sedating effect
             within 24 hours of the craving provocation visit; Current use of any nicotine
             replacement therapy.

          -  Substance abuse: Recent history or current history (within the last 1 year) of alcohol
             or other substance abuse.
Clinical trial NCT01389973 (phase 2, status: completed)
Conditions: primary biliary cirrhosis
ICD codes: K74.3
Drugs: ustekinumab 90 mg, ustekinumab 45 mg, ustekinumab 180 mg, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have proven or are likely to have Primary Biliary Cirrhosis (PBC)

          -  Be on a stable dose of ursodeoxycholic acid for at least 6 months prior to Week 0

          -  Have screening alkaline phosphatase (ALP) level > 1.67 ULN (the upper limit of normal)

          -  Have screening laboratory test results within protocol-specified limits

          -  Have no history of latent or active tuberculosis (TB) prior to screening and no signs
             or symptoms suggestive of active TB upon medical history and/or physical examination.

        Exclusion Criteria:

          -  Has history of gastrointestinal bleeding, secondary to portal hypertension, hepatic
             encephalopathy, or ascites requiring treatment with diuretics

          -  Has a screening direct bilirubin > 1.0 mg/dL

          -  Has a previous liver histology with a diagnosis of steatohepatitis or has a high risk
             of nonalcoholic steatohepatitis

          -  Has a previous liver histology with a diagnosis of chronic autoimmune hepatitis or has
             a high risk of autoimmune hepatitis overlap syndrome

          -  Testing positive for surface antigen (HBsAg+), regardless of the results of other
             hepatitis B tests

          -  Have used colchicine, methotrexate (MTX), azathioprine (AZA), or systemic
             corticosteroids within 3 months prior to the first administration of study drug.
Clinical trial NCT01256372 (phase 2, status: completed)
Conditions: cardiac surgery, coronary artery bypass, aortic aneurysm, valve surgery, kidney diseases
ICD codes: I97.110, I97.120, I97.710, I97.190, I97.790, I97.111, I97.121, T82.212S, T82.213S, T82.211S, T82.212A, T82.212D, T82.213A, T82.213D, I12.9, N18.9, Q61.9, I12.0, D63.1, N18.1, N18.5
Drugs: ap214, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Has signed the trial-specific informed consent form.

          2. Patients ≥ 18 years old, male or female, not of childbearing potential (postmenopausal
             or permanently sterilized, e.g. tubal ligation, hysterectomy, bilateral
             salpingectomy), regardless of ethnicity.

          3. Patients undergoing combined coronary artery bypass grafting (CABG) surgery and
             surgery of one or more cardiac valve (valve(s) surgery), or

          4. Patients undergoing surgery of more than one cardiac valve (valves surgery), or

          5. Patients undergoing surgery of the aortic root or ascending part of the aorta, or

          6. Patients undergoing surgery of the aortic root or ascending part of the aorta,
             combined with CABG and/or valve(s) surgery, or

          7. Patients with stage III chronic kidney disease (eGFR 30-59 ml/min determined by the
             Modification of Diet in Renal Disease (MDRD formula)) undergoing CABG or Valve surgery

        Exclusion Criteria:

          1. Cardiac surgery to be performed "off pump" without cardiopulmonary bypass.

          2. Cardiac surgery to be performed with hypothermic circulatory arrest.

          3. Confirmed or suspected endocarditis.

          4. EF ≤ 20%, evaluated within 2 months prior to screening visit.

          5. Requiring a reoperation on one of the valves within 3 months following the original
             valve surgical procedure.

          6. Active peptic ulcer disease and gastritis.

          7. Receiving dopamine, adrenalin or noradrenalin at any dose at any time 14 days prior to
             Day of surgery.

          8. Known or suspected hypersensitivity to the investigational medicinal product.

          9. Current participation in any other interventional clinical trial.

         10. Previously dosed with AP214.

         11. Use of investigational medicinal products within the previous 6 months.

         12. Body weight above 130 kg.

         13. History of any organ transplant.

         14. Women who are of childbearing potential, pregnant, or breast-feeding.

         15. Current abuse of alcohol or substance, according to the investigator's medical
             judgment.

         16. Has a mental incapacity or language barriers precluding adequate understanding of
             trial procedures.

         17. Any history of cancer within the last 2 years

         18. Any history of dialysis.

         19. Is considered by the Investigator unsuitable to participate in the trial for any other
             reason, for instance due to a significant serious underlying condition.
Clinical trial NCT00663117 (phase 2, status: completed)
Conditions: inflammation, crohn's disease
ICD codes: H01.9, H30.93, H05.00, H30.003, H30.013, H30.033, H30.103, K50.90, K50.913, K50.914, K50.911, K50.912, K50.918, K50.919
Drugs: naltrexone-hcl, placebo
SMILES: [H][C@@]12OC3=C(O)C=CC4=C3[C@@]11CCN(CC3CC3)[C@]([H])(C4)[C@]1(O)CCC2=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  All subjects must give written informed consent

          -  Male or female subjects, > 18 years

          -  Patients must have endoscopic, histologic, or radiographic confirmed Crohn's Disease.

          -  Patients must have a Crohn's Disease Activity Index (CDAI) of at least 220 at Baseline

          -  Stable doses of medications for Crohn's disease over proceeding 4 weeks (for
             aminosalicylates and steroids: prednisone of 10mg or less daily and Entocort 3 mg/ day
             are allowed), and 12 weeks for azathioprine or 6-mercaptopurine.)

        Exclusion Criteria:

          -  Subjects with ostomies or ileorectal anastomosis from prior surgical colectomy.

          -  Subjects who received infliximab (Remicade) within 8 weeks of study screening or
             humira for 4 weeks.

          -  Subjects requiring steroids either intravenously or prednisone >10mg /day or Entocort
             > 3 mg daily.

          -  Subjects with short-bowel syndrome.

          -  Abnormal liver enzymes at screening visit or known hepatitis or cirrhosis

          -  Hemoglobin less than 10.

          -  Subjects with cancer (other than skin cancer) in past 5 years.

          -  Women of childbearing potential unless surgically sterile or using adequate
             contraception (either IUD, oral or deport contraceptive, or barrier plus spermicide),
             and willing and able to continue contraception for 3 months after the completion of
             the study.

          -  Women who are pregnant or breastfeeding
Clinical trial NCT00280748 (phase 2, status: terminated)
Conditions: lung cancer, metastatic cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: pemetrexed disodium
SMILES: [H][C@@](CCC(O)=O)(NC(=O)C1=CC=C(CCC2=CNC3=C2C(O)=NC(=N)N3)C=C1)C(O)=O
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)

          -  Must have evidence of brain metastases by MRI or CT scan

        PRIOR CONCURRENT THERAPY:

          -  Recovered from prior oncologic or major surgery

          -  Prior resection of all brain metastases or only site of brain metastases allowed
             provided there is radiologically evaluable intracranial metastases

          -  No prior cranial irradiation, including stereotactic radiosurgery

          -  More than 30 days since prior non-approved or investigational drug

          -  No other concurrent chemotherapy, immunotherapy, hormonal therapy, radiotherapy,
             surgery, or experimental medications

               -  No single brain metastases or oligometastatic disease amenable to surgical
                  resection or radiosurgery

          -  Relapsed NSCLC with brain metastases allowed

          -  Not a candidate for double-agent or platinum-based chemotherapy

          -  No leptomeningeal metastases

          -  No clinically relevant (defined by physical exam) pleural effusions or ascites that
             cannot be controlled with drainage or other procedures

        Inclusion Criteria:

          -  Karnofsky performance status 70-100% OR ≥ 70 years of age

          -  Life expectancy > 3 months

          -  Absolute neutrophil count (ANC) > 1,500/mm³

          -  Platelet count > 100,000/mm³

          -  Hemoglobin ≥ 8 g/dL

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 times upper
             limit of normal (ULN)

          -  Bilirubin ≤ 1.5 times ULN

          -  Creatinine clearance ≥ 45 mL/min

          -  Able to take vitamins, folic acid, and corticosteroids

        Exclusion Criteria:

          -  Contraindication or intolerance to corticosteroid therapy

          -  Other malignancies within the past 5 years and disease-free OR prognosis is best
             defined by the NSCLC in the opinion of the attending physician

          -  Pregnant or nursing

          -  Positive pregnancy test

          -  Fertile patients must use effective contraception

          -  HIV positive

          -  Severe hypersensitivity to pemetrexed disodium

          -  Unable to discontinue NSAIDs for ≥ 5 days

          -  History of underlying dementia, Parkinson's disease, or Alzheimer's disease
Clinical trial NCT01500161 (phase 2, status: terminated)
Conditions: acute myelogenous leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia, hodgkins disease, non-hodgkins lymphoma, aplastic anemia, multiple myeloma, myelodysplastic syndrome
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, A87.2, K52.832, D72.111, C91.11, C91.12, C91.10, C91.11, C91.12, C91.10, C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, D61.3, D61.9, D61.09, D61.1, D61.2, D61.89, C90.01, C90.02, C90.00, D46.9, D46.C, D46.Z
Drugs: busulfan, clofarabine, fludarabine, melphalan, carmustine, etoposide, cytarabine
SMILES: CS(=O)(=O)OCCCCOS(C)(=O)=O, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, ClCCN(CCCl)P1(=O)NCCCO1, N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O, ClCCNC(=O)N(CCCl)N=O, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, ClCCN(CCCl)P1(=O)NCCCO1
Reason stopped: 
    insufficient accruals
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients < 65 years with hematologic malignancies needing stem cell transplant but do
             not have HLA-matched sibling donor. Patients with the following diagnosis will be
             included:

               -  AML in first or subsequent complete or partial remissions

               -  ALL in first or subsequent complete or partial remissions

               -  CLL in second remission or more advanced disease

               -  CML who has failed tyrosine kinase inhibitors

               -  Hodgkin's disease who relapse after autologous transplant

               -  Non-Hodgkin's lymphoma who relapse after autologous transplant or NK-cell
                  lymphoma in CR1

               -  Aplastic anemia patients

               -  Multiple myeloma in second remission or moer advanced disease, including those
                  who have failed an autologous transplant

               -  Myelodysplastic syndrome in first or subsequent complete or partial remission

          -  Patients must have 6/6, 5/6 or 4/6 molecular matches from unrelated UCB donors.
             Matching will be done for A, B, and DR. Matching at DR will be confirmed by molecular
             typing.

          -  Patients must be documented to be HIV negative. Screening must have been performed
             within previous 6 months.

          -  Patients must be able to give written consent.

        Exclusion Criteria:

          -  Patient is excluded if all of the Inclusion criteria above isn't met.
Clinical trial NCT01506908 (phase 2, status: completed)
Conditions: smoking dependence, smoking
ICD codes: F10.20, F11.20, F12.20, F14.20, F16.20, F18.20, Z99.0, O99.334, O99.335, Y93.G2, O99.330, O99.331, O99.332, O99.333
Drugs: oral nicotine, placebo
SMILES: CN1CCC[C@H]1C1=CN=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Current cigarette smokers who have smoked regularly, and smoke more than 20 cigarettes
             per day on a regular basis for at least a year;

          -  Good general health with (in the opinion of the investigator) no clinically
             significant and relevant abnormalities of medical history.

        Exclusion Criteria:

          -  Any disease that may interfere with the absorption, metabolism or excretion of the
             study product.

          -  A medical condition that might jeopardise the safety of the subject or the validity of
             the study results. For example, recent myocardial infarction or cerebrovascular
             incident (within 12 weeks of the screening visit), phenylketonuria, unstable or
             worsening angina pectoris, Prinzmetals angina or severe cardiac arrhythmia
Clinical trial NCT01126177 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: interferon beta 1a, placebo
SMILES: [Na+].[Cl-], CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        1. Male or female aged 18 to 65 years of age at the time of screening.

          2. Symptoms of asthma for at least 2 years pri or to the Screening Visit, confirmed by a
             medical history and:

               1. ≥12% and 200mL bronchodilator reversibility at screening or documented in the
                  past, OR,

               2. evidence of bronchial hyper-responsiveness at screening or documented in the
                  past, OR,

               3. a documented hospital admission (including an Accident and Emergency admission)
                  for asthma since the age of 18, OR.

               4. documented evidence that they have attended their GP surgery, out-of-hours clinic
                  (or alternative health care provider) for worsening of asthma symptoms, since the
                  age of 18

          3. Must answer "Yes" to the question "Does a cold make your asthma worse?"

          4. To have had at least one asthma exacerbation suspected to have been caused by a
             respiratory virus in the last 24 months which required the use of oral steroids and/or
             additional treatment with antibiotics on one or more occasion.

          5. Must be taking regular inhaled corticosteroids.

          6. Pre-bronchodilator FEV1 ≥ 40 % predicted at screening.

          7. Post-bronchodilator FEV1 ≥ 50 % predicted at screening.

          8. Provide written informed consent.

          9. Females of childbearing potential must be using a medically acceptable adequate form
             of birth control and agree to maintain this usage throughout the duration of and four
             weeks post the Treatment Phase of the study.

         10. Motivation (in the Investigator"s opinion) to complete all study visits, the ability
             to communicate well with the Investigator and be capable of understanding the nature
             of the research and its treatment including its risks and benefits.